Cargando…

Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in a Neonatal Intensive Care Unit in China

BACKGROUND: Ceftazidime/avibactam (CZA)-resistant carbapenem-resistant Klebsiella pneumoniae (CRKP) infections occur in adults worldwide but are rarely observed in neonates. We evaluated the activities of CZA against CRKP and described the clinical and molecular epidemiology of CZA-resistant CRKP in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Juanjuan, Yang, Junwen, Hu, Fupin, Gao, Kaijie, Sun, Jiufeng, Yang, Junmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394509/
https://www.ncbi.nlm.nih.gov/pubmed/32801794
http://dx.doi.org/10.2147/IDR.S256922
_version_ 1783565238775316480
author Zhou, Juanjuan
Yang, Junwen
Hu, Fupin
Gao, Kaijie
Sun, Jiufeng
Yang, Junmei
author_facet Zhou, Juanjuan
Yang, Junwen
Hu, Fupin
Gao, Kaijie
Sun, Jiufeng
Yang, Junmei
author_sort Zhou, Juanjuan
collection PubMed
description BACKGROUND: Ceftazidime/avibactam (CZA)-resistant carbapenem-resistant Klebsiella pneumoniae (CRKP) infections occur in adults worldwide but are rarely observed in neonates. We evaluated the activities of CZA against CRKP and described the clinical and molecular epidemiology of CZA-resistant CRKP in a NICU prior to CZA approval in China. METHODS: A laboratory-based surveillance of CRKP was conducted from July 2017 to June 2018. Clinical data were initially reviewed. Antimicrobial susceptibility was determined by the broth microdilution method. CZA-resistant CRKP isolates were submitted to carbapenemase types screening and multilocus sequence typing. RESULTS: Over 23.3% (10/43) of CRKP strains were resistant to CZA, MIC(50) and MIC(90) values being 0.5 μg/mL and >32μg/mL, respectively. Most neonates shared similar clinical features with cesarean (n=8), preterm birth (n=6), low birth weight (n=5), and exposure to carbapenems/β-lactam (n=8). All CZA-resistant CRKP isolates were highly resistant to most tested drugs except for polymyxin B (POL) and tigecycline (TGC). CZA-resistant CRKP isolates showed greater sensitivity to amikacin (AMK), nitrofurantoin (NIT), levofloxacin (LVX) and ciprofloxacin (CIP), compared with CZA-sensitive CRKP. All CZA-resistant CRKP isolates harbored carbapenemase genes, bla(kpc-2) (n=5) being predominant, followed by bla(NDM-1) (n=4) and bla(NDM-5) (n=2). Among these CZA-resistant CRKP isolates, a total of eight different STs were identified. CRKP harboring KPC belonged to ST1419, ST37 and ST11, while NDM types were assigned to ST784, ST1710, ST37 and ST324. Furthermore, other β-lactamase genes including bla(SHV) and bla(CTX-M) were also found. CONCLUSION: Over 23.3% of CRKP strains isolated from neonates were resistant to CZA. Cesarean, preterm birth, low birth weight, and exposure to carbapenems/β-lactam were similar clinical features of most neonates with CZA-resistant CRKP. The predominant carbapenemases of CZA-resistant CRKP were KPC-2 and NDM-1, and KPC-2 producing K. pneumoniae assigned into 3 STs, which indicate the genetic diversity of clinical CZA-resistant CRKP isolates.
format Online
Article
Text
id pubmed-7394509
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73945092020-08-13 Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in a Neonatal Intensive Care Unit in China Zhou, Juanjuan Yang, Junwen Hu, Fupin Gao, Kaijie Sun, Jiufeng Yang, Junmei Infect Drug Resist Original Research BACKGROUND: Ceftazidime/avibactam (CZA)-resistant carbapenem-resistant Klebsiella pneumoniae (CRKP) infections occur in adults worldwide but are rarely observed in neonates. We evaluated the activities of CZA against CRKP and described the clinical and molecular epidemiology of CZA-resistant CRKP in a NICU prior to CZA approval in China. METHODS: A laboratory-based surveillance of CRKP was conducted from July 2017 to June 2018. Clinical data were initially reviewed. Antimicrobial susceptibility was determined by the broth microdilution method. CZA-resistant CRKP isolates were submitted to carbapenemase types screening and multilocus sequence typing. RESULTS: Over 23.3% (10/43) of CRKP strains were resistant to CZA, MIC(50) and MIC(90) values being 0.5 μg/mL and >32μg/mL, respectively. Most neonates shared similar clinical features with cesarean (n=8), preterm birth (n=6), low birth weight (n=5), and exposure to carbapenems/β-lactam (n=8). All CZA-resistant CRKP isolates were highly resistant to most tested drugs except for polymyxin B (POL) and tigecycline (TGC). CZA-resistant CRKP isolates showed greater sensitivity to amikacin (AMK), nitrofurantoin (NIT), levofloxacin (LVX) and ciprofloxacin (CIP), compared with CZA-sensitive CRKP. All CZA-resistant CRKP isolates harbored carbapenemase genes, bla(kpc-2) (n=5) being predominant, followed by bla(NDM-1) (n=4) and bla(NDM-5) (n=2). Among these CZA-resistant CRKP isolates, a total of eight different STs were identified. CRKP harboring KPC belonged to ST1419, ST37 and ST11, while NDM types were assigned to ST784, ST1710, ST37 and ST324. Furthermore, other β-lactamase genes including bla(SHV) and bla(CTX-M) were also found. CONCLUSION: Over 23.3% of CRKP strains isolated from neonates were resistant to CZA. Cesarean, preterm birth, low birth weight, and exposure to carbapenems/β-lactam were similar clinical features of most neonates with CZA-resistant CRKP. The predominant carbapenemases of CZA-resistant CRKP were KPC-2 and NDM-1, and KPC-2 producing K. pneumoniae assigned into 3 STs, which indicate the genetic diversity of clinical CZA-resistant CRKP isolates. Dove 2020-07-27 /pmc/articles/PMC7394509/ /pubmed/32801794 http://dx.doi.org/10.2147/IDR.S256922 Text en © 2020 Zhou et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhou, Juanjuan
Yang, Junwen
Hu, Fupin
Gao, Kaijie
Sun, Jiufeng
Yang, Junmei
Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in a Neonatal Intensive Care Unit in China
title Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in a Neonatal Intensive Care Unit in China
title_full Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in a Neonatal Intensive Care Unit in China
title_fullStr Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in a Neonatal Intensive Care Unit in China
title_full_unstemmed Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in a Neonatal Intensive Care Unit in China
title_short Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-Resistant Klebsiella pneumoniae in a Neonatal Intensive Care Unit in China
title_sort clinical and molecular epidemiologic characteristics of ceftazidime/avibactam-resistant carbapenem-resistant klebsiella pneumoniae in a neonatal intensive care unit in china
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394509/
https://www.ncbi.nlm.nih.gov/pubmed/32801794
http://dx.doi.org/10.2147/IDR.S256922
work_keys_str_mv AT zhoujuanjuan clinicalandmolecularepidemiologiccharacteristicsofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinaneonatalintensivecareunitinchina
AT yangjunwen clinicalandmolecularepidemiologiccharacteristicsofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinaneonatalintensivecareunitinchina
AT hufupin clinicalandmolecularepidemiologiccharacteristicsofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinaneonatalintensivecareunitinchina
AT gaokaijie clinicalandmolecularepidemiologiccharacteristicsofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinaneonatalintensivecareunitinchina
AT sunjiufeng clinicalandmolecularepidemiologiccharacteristicsofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinaneonatalintensivecareunitinchina
AT yangjunmei clinicalandmolecularepidemiologiccharacteristicsofceftazidimeavibactamresistantcarbapenemresistantklebsiellapneumoniaeinaneonatalintensivecareunitinchina